Ab den 7.Mai wird bei F-a-D : SARS,TB und MS neu ins Programm genommen!
The first target is Severe Acute Respiratory Syndrome (SARS) and subsequent ones may include Tuberculosis (TB). SARS is believed to be caused by a virus belonging to the corona family, similar to one which can cause gastroenteritis. In general, antibiotics are of little use against a viral infection and survival can depend on the body's own immune system. Vaccines can play a valuable role priming the immune system to respond to viral proteins, but only if the outer surface of the protein does not rapidly mutate and change creating different strains (like HIV does). The ideal drug inhibits the development of the virus by interacting at a site or pocket of the protein much like a key turns in a lock.
The drug target is the active site of a protease which is a key enzyme in the coronavirus polyprotein and quite unlike other viral and human proteins. The results will be made available to recognised research groups around the world.
Multiple sclerosis is one of the most common diseases of the central nervous system (brain and spinal cord). Loss of myelin from around the nerves is accompanied by a disruption in the ability of the nerves to conduct electrical impulses to and from the brain and this produces the various symptoms of the disease. The symptoms of MS vary depending on the part of the brain affected but can include fatigue, weakness, spasticity, balance problems, bladder and bowel problems, numbness, vision loss, tremors and depression. Living with MS for 20 or 30 years may result in substantial disability even if the progress towards disability is slow and in the first 10 or 15 years he or she is relatively mildly affected. About 15% of people with MS become severely disabled (i.e.having to use a wheelchair on a full-time basis).
There is no cure for MS although current therapies can slow the progression of disability as well as reduce the severity and frequency of exacerbations. Much more research is need to understand the disease, the role of various proteins and the consequences of inhibiting their functions. Identifying small molecules which can bind to these proteins is a first step. The results of this project are being made available to Dr Ramachandran Murali of University of Pennsylvania, Philadelphia, USA who is currently a visiting academic at the Department of Pathology, University of Oxford, UK.
Es wird auch die neuen Clients für Morgen geben!
Windows Version 1.21k
Linux Version 1.21k